...Satoshi Igawa; Jiichiro Sasaki; Sakiko Otani; Mikiko Ishihara; Akira Takakura; Masato Katagiri; Noriyuki Masuda Background: Gefitinib treatment has come to be recognized as the standard therapy for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR...

... mutations in non-small cell lung cancer (NSCLC), and predict higher clinical outcomes following treatment with gefitinib. The objective of this study was to evaluate the differential clinical outcomes of gefitinib in patients with NSCLC according to the type of active EGFR mutation, i.e. exon 19 deletion...

... cancer (NSCLC) patients [ 2,3 ] and their association with remarkable response to EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib [ 2,3,4,5,6,7,8,9,10,11 ], have led to a paradigm shift in the management of advanced NSCLC. Adenocarcinoma Epidermal growth factor receptor...

...: Salvage treatment for acquired resistance to gefitinib has yet to be developed. We conducted the first prospective phase II study of gefitinib readministration in previous gefitinib responders. Methods: Gefitinib (250 mg/day) was readministered to patients with advanced/metastatic non-small cell lung...

... growth factor receptor (EGFR) mutation status and serum C-reactive protein (CRP) for their associations with response to gefitinib therapy and for prognostic impacts. Methods: Serum levels of CRP from 79 Japanese patients with advanced nonsquamous NSCLC were measured before the start of gefitinib. We...

... advantage from systemic chemotherapy. A further advantage was reported when docetaxel and pemetrexed were used as second-line treatment after failure of first-line platinum-based chemotherapy. Furthermore, the biologic therapies targeting the epidermal growth factor receptor – erlotinib and gefitinib – have...

... growth factor receptor (EGFR) inhibitor gefitinib and docetaxel in a phase II study following gemcitabine failure. Methods: EGFR overexpression was not required. The initial docetaxel dose was 75 mg/m 2 on day 1 every 21 days. Due to febrile neutropenia in 8 of the first 18 patients, the dose was reduced...

...Hyo Song Kim; Keunchil Park; Hyun Jung Jun; Seong Yoon Yi; Jeeyun Lee; Jin Seok Ahn; Yeon Hee Park; Seonwoo Kim; Sangcheol Lee; Myung-Ju Ahn Background: The aim of this study was to analyze the survival difference between advanced non-small cell lung cancer (NSCLC) patients in the pre-gefitinib...

...Francesco Boccardo; Alessandra Rubagotti; Giario Conti; Michele Battaglia; Giorgio Cruciani; Antonio Manganelli; Sergio Ricci; Alberto Lapini Background: Abnormal epidermal growth factor receptor expression and pre-clinical data prompted us to investigate the activity of gefitinib, a selective...

... clones. The association between EGFR mutation status and the clinical outcome of gefitinib treatment was investigated. For mutation-positive cases, the percentage of mutated clones from the total number of clones was calculated. This ratio was used as the quantitative index of EGFR mutations. Results: We...

...Michail Ignatiadis; Aris Polyzos; George P. Stathopoulos; Evangelos Tselepatiotis; Charalambos Christophylakis; Kostas Kalbakis; Lambros Vamvakas; Athanasios Kotsakis; Anna Potamianou; Vassilis Georgoulias Purpose: To evaluate the efficacy and tolerance of the docetaxel/gefitinib combination...

... of combining IFNα and gefitinib on colon cancer cell line growth. Methods: A panel of nine colon cancer cell lines were characterised for expression of HER1/EGFR and then treated with gefitinib alone, or IFNα alone, or IFNα plus gefitinib, following a pre-treatment using vehicle or IFNα. Crystal violet...

...Annette N.Y. Poon; Simon S.M. Ho; Winnie Yeo; Tony S.K. Mok A woman with stage IIIb non-small cell lung cancer (NSCLC) developed disease progression with brain metastases during chemotherapy. Due to unusual circumstances, the patient received gefitinib alone, without the use of corticosteroid...